Search Results
Expert report on survival data from pivotal trials with PARP inhibitors for BRCA-mut. Ovarian Cancer
Updates in PARP inhibition for ovarian cancer
PARP Inhibition Improves Outcomes in Patients With BRCA-Mutated Ovarian Cancer
PARP inhibitors in ovarian cancer: Clinical updates from SGO 2023
Clinical Data with PARP Inhibitors in Ovarian Cancer
Personalizing Advanced Ovarian Cancer Treatment With PARP Inhibitors and Novel Approaches
Final OS results from PAOLA-1 evaluating 1L maintenance olaparib plus bevacizumab
SOLO-1: Olaparib or placebo for patients with newly diagnosed BRCA-mutated advanced ovarian cancer
The Therapeutic Potential of Novel PARP Inhibitors in the Clinic for Epithelial Ovarian Cancer
PARP inhibitors as first-line maintenance therapy in ovarian cancer
PARP inhibitors at the crossroads in ovarian cancer: 2022 ESMO Florida
Precision Medicine for Ovarian Cancer (2021)
